FDA and Prescription Drug Pricing - Health Care Compliance Brief

Lower Prescription Drug Prices – A Tri-Partisan Call Across America

Health Populi

AUGUST 3, 2018

A new poll jointly conducted by Politico and the Harvard Chan School of Public Health bolsters my read on the latter issue – prescription drug pricing, which has become a mass popular culture union. This is the tactic that most Americans say could lower prescription drug prices. Why should U.S.

Prescription Drug Pricing

Prescription Drug Pricing FDA Public Health Medicare

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

OCTOBER 7, 2022

Food and Drug Administration (FDA) advisory committees, an analysis of the key patents covering drugs recently approved by the FDA, and an examination of high-risk cardiovascular devices approved by the FDA for use in children and adolescents. Improving the Use of FDA Advisory Committees. N Engl J Med.

Prescription Drug Pricing

Prescription Drug Pricing FDA Medicare Medicare

Vendor Notebook: new tools and acquisitions from OptumRx, ScionHealth, others

Healthcare IT News - Telehealth

JANUARY 25, 2023

OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescription drug prices. FDA is currently reviewing use of Selux's NGP Gram-Negative panel. Inspira Technologies said it received patent approval from the U.S.

Prescription Drug Pricing

Prescription Drug Pricing Doctors FDA Health Insurance

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Health Populi

JANUARY 29, 2019

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. Thus far, the FDA has been welcoming to these concepts.

Prescription Drug Pricing

Prescription Drug Pricing FDA Patient Advocacy Governance

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

Kaiser Health News

MARCH 15, 2023

“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”

Doctors

Doctors Prescription Drug Pricing FDA COVID-19

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

Kaiser Health News

MARCH 15, 2023

“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”

Doctors

Doctors Prescription Drug Pricing FDA COVID-19

CVS + Aetna: Inflection Point in US Healthcare, Merger Approved Update

Health Populi

OCTOBER 12, 2018

Eli Lilly is currently under investigation for working, under your tenure, with other drug companies to needlessly raise the price of insulin.” ” Second, the National Academy of Science published a well-researched report supporting government prescription drug price negotiation.

US Department of Health and Human Services

US Department of Health and Human Services Prescription Drug Pricing Health Insurance Medicare

Rx 2018: A New Era of Specialty Drugs, Telehealth, Mobile Apps and Value, IQVIA Reports

Health Populi

MARCH 13, 2018

Health Populi’s Hot Points: The big wild card in forecasting what prescription drug spending will look like in the U.S. is just how aggressive Dr. Alex Azar at the Department of Health and Human Services, and Dr. Scott Gottlieb at FDA, want to be regarding drug pricing.

Prescription Drug Pricing

Prescription Drug Pricing FDA Hospitals Medicare

The State of the Union for Prescription Drug Prices

Health Populi

FEBRUARY 4, 2020

voters’ priorities, across political party – prescription drug prices. voters in 2020 quite like supporting Medicare’s ability to negotiate drug prices with pharmaceutical companies, shown by the October 2019 Kaiser Family Foundation Health Tracking Poll. Few issues unite U.S.

Prescription Drug Pricing

Prescription Drug Pricing Medicare Medicare Health Insurance

Health Provider News

Hall Render

MAY 10, 2024

Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass. Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass.

Nursing Homes

Nursing Homes Nurses Hospitals Medicaid

Health Provider News – February 18, 2022

Hall Render

FEBRUARY 18, 2022

Meet new FDA chief Dr. Robert Califf: 5 things to know. Only 14% of Hospitals Met Price Transparency Rule Compliance. Bill on prescription drug pricing inspires support from Maine residents, opposition from pharmaceutical industry. Hospitals urge HHS to fix, not end, direct contracting model.

COVID-19

COVID-19 Nursing Homes Nurses COVID-19 Vaccine

The Gap Between the Trump Administration’s Promise of Reducing Rx Costs for Consumers and What People Really Want

Health Populi

MAY 14, 2018

This is what happened to pharma stock prices on Friday after President Trump and Secretary of Health and Human Services Alex Azar outlined their new policies focusing on prescription drug prices. The graph is the Nasdaq U.S. Foreign governments’ “free-riding” Americans’ investment in innovation.

Prescription Drug Pricing

Prescription Drug Pricing Governance ACA Medicare

What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices

Jane Sarashon

NOVEMBER 14, 2024

consumer dissatisfaction with drug prices — across political party identification. insured consumers’ perspectives on prescription drug pricing and the role of PBMs (pharmacy benefit managers). 9 in 10 insured Americans felt that prescriptions are more expensive in the U.S.

Prescription Drug Pricing

Prescription Drug Pricing ACA Health Insurance Medicaid

Guest Post – Second Circuit Rejects Manufacturer’s Plan to Share Cost of Expensive Drug with Medicare Part D Beneficiaries

Drug & Device Law

OCTOBER 10, 2022

The manufacturer sought to cover Medicare patients’ Part D cost-sharing obligations for the drug – which were estimated at approximately $13,000 per year – but the OIG said “no thanks,” and the Second Circuit has affirmed that outcome. A little background is in order. ATTR-CM only affects about 150,000 Americans, who are mostly elderly.

Medicare

Medicare Medicare FDA Prescription Drug Pricing

Health Care Compliance Brief

Lower Prescription Drug Prices – A Tri-Partisan Call Across America

Monthly Round-Up of What to Read on Pharma Law and Policy

Trending Sources

Vendor Notebook: new tools and acquisitions from OptumRx, ScionHealth, others

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

CVS + Aetna: Inflection Point in US Healthcare, Merger Approved Update

Rx 2018: A New Era of Specialty Drugs, Telehealth, Mobile Apps and Value, IQVIA Reports

The State of the Union for Prescription Drug Prices

Health Provider News

Health Provider News – February 18, 2022

The Gap Between the Trump Administration’s Promise of Reducing Rx Costs for Consumers and What People Really Want

What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices

Guest Post – Second Circuit Rejects Manufacturer’s Plan to Share Cost of Expensive Drug with Medicare Part D Beneficiaries

Stay Connected